When pelvic radiation therapy saves lives from cancer, it can also leave behind a painful legacy in healthy tissues. Radiation cystitis—inflammation and damage to the bladder lining following radiotherapy—represents one of the most challenging late complications for cancer survivors. A new review published in Current Urology Reports brings updated evidence on hyperbaric oxygen therapy (HBOT) as a treatment option, confirming its position as the only therapy with proven efficacy for this debilitating condition.
The Hidden Burden of Pelvic Radiation
Approximately 15–20% of patients receiving pelvic radiotherapy for prostate, cervical, bladder, or rectal cancers develop radiation-induced bladder injury. The damage often emerges months or years after treatment, when patients expect to be moving forward with their lives. Symptoms range from urinary frequency, urgency, and hematuria to intractable bleeding and bladder contracture. For severe cases, treatment options have traditionally been limited to symptomatic management or invasive procedures up to and including cystectomy with urinary diversion.
“Radiation cystitis remains one of the most frustrating complications for both patients and physicians,” note Dr. Harrington and Dr. Moses in their comprehensive review. “The therapeutic armamentarium has been historically limited, making HBOT’s unique mechanism particularly valuable.”
How HBOT Works for Radiation Injury
The therapeutic rationale for HBOT in radiation cystitis addresses the fundamental pathophysiology of radiation damage. Ionizing radiation creates progressive vascular injury—narrowing of small vessels, tissue hypoxia, and impaired cellular regeneration. This creates a self-perpetuating cycle where hypoxic tissue becomes increasingly vulnerable to further damage and less capable of healing.
HBOT breaks this cycle by delivering 100% oxygen at pressures typically around 2.0–2.4 atmospheres absolute (ATA). Under these conditions, plasma oxygen content increases sufficiently to oxygenate tissues independently of hemoglobin transport. The resulting hyperoxia stimulates angiogenesis, mobilizes stem cells, reduces inflammation, and restores the cellular energy metabolism necessary for tissue repair.
The Evidence Base: What the 2026 Review Found
Harrington and Moses’s updated analysis, building on the foundational 2018 scoping review, examined recent literature on HBOT for radiation cystitis. Their findings reinforce the therapy’s established benefits while highlighting important nuances in patient selection and treatment protocols.
The review cites response rates ranging from 60% to 90% across multiple cohort studies, with durable benefits persisting at long-term follow-up. Notably, patients treated earlier in their disease course—before extensive fibrosis develops—demonstrate superior outcomes. The typical treatment protocol involves 30–40 daily sessions, each lasting approximately 90 minutes.
The 2023 Cochrane systematic review on late radiation tissue injury (Lin et al.) similarly concluded that HBOT reduces pain and improves healing in radiation-induced injuries, though the authors noted the need for larger randomized trials with standardized protocols.
FDA Position: Cleared, But Context Matters
The U.S. Food and Drug Administration has cleared HBOT specifically for “delayed radiation injury (soft tissue and bony necrosis)“—a classification that encompasses radiation cystitis. This clearance places radiation injury among the established, evidence-based indications for hyperbaric medicine, alongside decompression sickness, carbon monoxide poisoning, and certain non-healing wounds.
However, the FDA maintains strict boundaries around promotional claims. In its consumer guidance, the agency emphasizes that HBOT is not proven for cancer treatment itself, nor for autism, Alzheimer’s disease, Lyme disease, or the various wellness applications sometimes marketed by commercial hyperbaric facilities. The FDA specifically recommends seeking treatment at UHMS-accredited facilities when HBOT is indicated for approved uses.
The August 2025 FDA safety letter to healthcare providers serves as an additional reminder that HBOT delivery requires rigorous adherence to manufacturer protocols. The communication documented fire incidents, injuries, and deaths associated with improper chamber operation—underscoring that even established indications require appropriate clinical settings.
Clinical Integration and Patient Selection
Contemporary practice for radiation cystitis typically follows a graduated approach. Conservative measures including bladder irrigation, intravesical therapy, and hyperbaric oxygen represent first-line interventions for moderate to severe cases. HBOT is generally considered when hematuria persists despite conservative management, or when patients wish to avoid more invasive interventions.
The UHMS consensus guidelines suggest that early referral—ideally before the development of severe fibrosis or bladder contracture—optimizes therapeutic outcomes. Contraindications include untreated pneumothorax, certain chemotherapy agents, and active malignancy in the treatment field (the latter because HBOT’s angiogenic effects could theoretically stimulate tumor growth, though evidence remains limited).
Looking Forward
Research continues to refine HBOT’s role in radiation injury management. Ongoing trials are exploring optimal pressure and duration protocols, combination strategies with other regenerative therapies, and predictive biomarkers for treatment response. The growing recognition of radiation cystitis as a quality-of-life issue for cancer survivors has prompted increased attention from both urologists and hyperbaric medicine specialists.
For the estimated thousands of cancer survivors grappling with radiation-induced bladder dysfunction, HBOT represents a rare therapeutic bright spot—a treatment that addresses the root cause of their symptoms rather than merely masking them. As the evidence base continues to mature, the challenge lies in ensuring appropriate access to this specialized therapy for patients who stand to benefit most.
HBOToday Editorial provides news and analysis on hyperbaric medicine research and policy. This article reports on peer-reviewed findings and regulatory positions; it does not constitute medical advice. Consult qualified healthcare providers for treatment decisions.